ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Rare Germline
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 22 citations in OpenAlex.
- Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.Haematologica · 2026Article
- Integrating enriched case data from national laboratory testing with population-based case-control analyses: a novel statistical likelihood-ratio methodology for PS4 applied to 325,345 breast cancer cases and 671,006 controls.medRxiv : the preprint server for health sciences · 2026Article
- Multiple myeloma risk linked to DNA damage response genes.Journal of hematology & oncology · 2026Article
- Implications of DNA damage response and immunotherapy in tumor therapy.Cell communication and signaling : CCS · 2025Review
- Intractable thrombocytopenia in a patient with atypical ataxia-telangiectasia: a case report.BMC medical genomics · 2025Article
- Fundamental prognostic difference of ATM gene mutation and deletion in newly diagnosed mantle cell lymphoma.Molecular medicine (Cambridge, Mass.) · 2025Article
- Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy.Nature genetics · 2025Article
- ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.Leukemia · 2025Article
- Rare germline ATM variants predispose to secondary cancer in chronic lymphocytic leukaemia patients.Cancer communications (London, England) · 2025Article
- Investigating the influence of germlineHaematologica · 2025Article
- Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies.Biomarker research · 2024Review
- Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment.Cancers · 2024Review
- Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings.Haematologica · 2024Article
- Characterization of time toxicity in older patients with metastatic breast cancer.Breast cancer research and treatment · 2024Article
- Evaluation of theHaematologica · 2024Article
- Genotoxicity Associated with Retroviral CAR Transduction of ATM-Deficient T Cells.Blood cancer discovery · 2024Article
- Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes.HemaSphere · 2024Article
- The molecular map of CLL and Richter's syndrome.Seminars in hematology · 2024Review
- Clinical Risks for Chronic Lymphocytic Leukemia.Journal of the National Comprehensive Cancer Network : JNCCN · 2024Review
- Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.Research square · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Funding
Abstract
purposeGermline missense variants of unknown significance in cancer-related genes are increasingly being identified with the expanding use of next-generation sequencing. The ataxia telangiectasia-mutated (
methodsWe identified 3,128 patients (including 825 patients with CLL) in our hematologic malignancy clinic who had received clinical-grade sequencing of the entire coding region of
resultsRare germline
conclusionGermline
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.